The Long-Term Outcome of Medical Therapy for BPH Stephan Madersbacher, Martin Marszalek, Jakob Lackner, Peter Berger, Georg Schatzl  European Urology  Volume 51, Issue 6, Pages 1522-1533 (June 2007) DOI: 10.1016/j.eururo.2007.03.034 Copyright © 2007 European Association of Urology Terms and Conditions

Fig. 1 Placebo response in long-term medical trials. The data of all trials listed in Table 1 were analysed; some trials contained no detailed information regarding maximum flow rate (Qmax). Each dot indicates the placebo arm of one study, the horizontal bars the respective mean values. European Urology 2007 51, 1522-1533DOI: (10.1016/j.eururo.2007.03.034) Copyright © 2007 European Association of Urology Terms and Conditions

Fig. 2 Impact of long-term medical therapy on lower urinary tract symptoms. All trials listed in Table 1 are included. Light-orange bar=active substance; Dark-orange bar=comparator, with the exception of two plant extract trials (see asterisk) — always placebo. European Urology 2007 51, 1522-1533DOI: (10.1016/j.eururo.2007.03.034) Copyright © 2007 European Association of Urology Terms and Conditions

Fig. 3 Impact of long-term medical therapy on maximum flow rate (Qmax). All trials listed in Table 1 are included. Light-orange bar=active substance; Dark-orange bar=comparator, with the exception of two plant extract trials (see asterisk) — always placebo. European Urology 2007 51, 1522-1533DOI: (10.1016/j.eururo.2007.03.034) Copyright © 2007 European Association of Urology Terms and Conditions

Fig. 4 Drop-out rates in long-term medical trials. Black=plant extracts; orange=α1-blocker; green=5α-reductase inhibitors; blue=combination therapy. European Urology 2007 51, 1522-1533DOI: (10.1016/j.eururo.2007.03.034) Copyright © 2007 European Association of Urology Terms and Conditions